• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Ticagrelor Market Trends

    ID: MRFR/Pharma/0324-CR
    101 Pages
    Kinjoll Dey
    July 2019

    Ticagrelor Market Research Report Information by Dosage (Mg) (90 MG and 60 MG), Route of Administration (Oral and Nasogastric Tube), Application (Acute Coronary Syndrome and Heart Surgeries (Angioplasty, Stent Placement and Coronary Artery Bypass Graft)) End User (Hospitals and Clinics and Ambulatory Centers) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast ti...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Ticagrelor Market Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Market Trends

    Key Emerging Trends in the Ticagrelor Market

    Cardiovascular disorders encompass a spectrum of heart-related conditions, including issues with blood vessels, structural abnormalities, and the formation of blood clots. Medications like ticagrelor play a crucial role in the treatment of cardiovascular disorders by intervening in blood coagulation and preventing platelet aggregation. Specifically, in cases of acute coronary syndrome, the combined use of ticagrelor and aspirin has demonstrated a reduction in the incidence of vascular deaths and myocardial infarctions compared to the combination of clopidogrel and aspirin.

    The growth of the ticagrelor market is closely linked to the escalating prevalence of cardiovascular disorders globally. For example, data from the American Heart Association reveals that in 2014, approximately 31% of deaths in the United States were attributed to cardiovascular disorders. Moreover, the economic impact of treating cardiovascular disorders in the Americas amounted to around USD 555 billion, underscoring the substantial burden of these conditions on healthcare systems.

    Similarly, in Europe, the European Heart Network reported in 2015 that there were 85 million individuals living with cardiovascular disorders. The high incidence of cardiovascular diseases (CVD) on a global scale is intricately connected to well-established risk factors such as hypertension, smoking, dyslipidemia (high cholesterol), diabetes, obesity, and unhealthy lifestyle choices. Notably, the United States holds the highest prevalence of obesity in North America, with 36.2% of its total population having a body mass index exceeding 30.0.

    This surge in obesity rates has indirect repercussions on the cardiovascular patient pool, further intensifying the demand for medications like ticagrelor. The intricate relationship between obesity and cardiovascular disorders is a concerning trend, as obesity is recognized as a significant risk factor for various heart-related conditions. As the population grappling with obesity continues to rise, it contributes to the overall burden of cardiovascular diseases, fostering a greater demand for effective pharmaceutical interventions such as ticagrelor.

    global prevalence of cardiovascular disorders, coupled with the rising incidence of obesity and its association with heart-related conditions, propels the demand for medications like ticagrelor. The compelling data from organizations like the American Heart Association and the European Heart Network underscores the urgent need for effective treatments in managing and mitigating the impact of cardiovascular diseases. The ticagrelor market is poised to play a crucial role in addressing these healthcare challenges as it continues to evolve and meet the demands of an increasingly cardiovascular-compromised population.

    Market Summary

    As per Market Research Future Analysis, the Ticagrelor Market is projected to grow at a CAGR of 6.4%, reaching USD 3.32 Billion by 2032. Ticagrelor is an antiplatelet drug that reduces platelet aggregation and prevents blood clots, primarily used in acute coronary syndrome (ACS). The market growth is driven by an increasing cardiovascular disease prevalence, particularly among the aging population, and advancements in product development. However, significant bleeding risks associated with Ticagrelor may hinder market expansion. The market is segmented by product type (0 mg and 60 mg Tablets), application (Clinic Pharmacies, Retail Pharmacies, Online Pharmacies), end-users (hospitals and clinics), and region (Americas, Europe, Asia-Pacific, Middle East, and Africa). The Americas is expected to dominate the market due to a high prevalence of chronic diseases and advanced healthcare infrastructure.

    Key Market Trends & Highlights

    The Ticagrelor Market is characterized by several key trends and opportunities.

    • Market Size: USD 3.32 Billion by 2032; CAGR: 6.4%
    • Major Opportunities: New product launches and R&D initiatives.
    • Market Restraints: Side effects like bleeding and dyspnea may limit usage.
    • Regional Growth: Asia-Pacific is the fastest-growing market due to rising disposable incomes.

    Market Size & Forecast

    Market Size USD 3.32 Billion by 2032
    CAGR 6.4%
    Largest Regional Market Americas
    Fastest Growing Region Asia-Pacific

    Major Players

    AstraZeneca, Eli Lilly, Ingelheim, Alexion, Roche, Amgen, Boehringer, Pfizer, Merck, GSK

    Market Trends

    Regional Analysis as per the Market Forecast. Market Competitive Landscape Developments in Market Value

    This report highlights the growth aspects of the Ticagrelor Market Revenue. Along with that, this report also intends to put up the competitive landscape and recent developments on the table to explain this global Atorvastatin API Market position.

    The ongoing evolution of the cardiovascular treatment landscape suggests that Ticagrelor is increasingly recognized for its role in improving patient outcomes, particularly in high-risk populations.

    U.S. Food and Drug Administration (FDA)

    Ticagrelor Market Market Drivers

    Market Growth Projections

    The Global Ticagrelor Market Industry is projected to experience robust growth over the coming years. With an estimated market value of 0.97 USD Billion in 2024, the industry is on a trajectory to reach 4.0 USD Billion by 2035. This growth is underpinned by a compound annual growth rate of 13.73 percent from 2025 to 2035. Such projections indicate a strong demand for Ticagrelor, driven by factors such as increasing cardiovascular disease prevalence, advancements in drug formulations, and enhanced healthcare access in emerging markets. These metrics highlight the potential for sustained growth in the Global Ticagrelor Market Industry.

    Growing Awareness and Education

    The increasing awareness and education regarding the importance of antiplatelet therapy contribute significantly to the Global Ticagrelor Market Industry. Healthcare providers are actively promoting the benefits of Ticagrelor in preventing cardiovascular events, leading to higher prescription rates. Initiatives by organizations such as the American Heart Association emphasize the need for effective treatment options, thereby influencing patient choices. This heightened awareness is likely to drive market growth, as more patients seek out Ticagrelor as a viable treatment option. The anticipated compound annual growth rate of 13.73 percent from 2025 to 2035 further illustrates this trend.

    Advancements in Drug Formulations

    Innovations in drug formulations and delivery mechanisms are propelling the Global Ticagrelor Market Industry forward. Recent advancements have enhanced the efficacy and safety profiles of Ticagrelor, making it a preferred choice among healthcare professionals. For example, the development of fixed-dose combinations with other antiplatelet agents has shown promising results in clinical trials. These innovations not only improve patient adherence but also expand the therapeutic applications of Ticagrelor. As a result, the market is anticipated to experience substantial growth, potentially reaching 4.0 USD Billion by 2035, driven by these advancements.

    Emerging Markets and Accessibility

    The expansion of healthcare infrastructure in emerging markets is a crucial driver for the Global Ticagrelor Market Industry. As countries invest in improving healthcare access, the availability of Ticagrelor is likely to increase, reaching a broader patient population. For example, nations in Asia and Africa are witnessing significant improvements in healthcare delivery systems, which facilitate the distribution of essential medications. This trend is expected to contribute to the overall market growth, as more patients gain access to effective antiplatelet therapies. The Global Ticagrelor Market Industry is poised to benefit from these developments, enhancing its reach and impact.

    Increasing Cardiovascular Diseases

    The rising prevalence of cardiovascular diseases globally is a primary driver for the Global Ticagrelor Market Industry. As heart-related ailments continue to escalate, the demand for effective antiplatelet therapies like Ticagrelor is expected to grow. For instance, the World Health Organization indicates that cardiovascular diseases account for approximately 32 percent of all global deaths. This alarming statistic underscores the urgent need for effective treatment options. Consequently, the Global Ticagrelor Market Industry is projected to reach 0.97 USD Billion in 2024, reflecting a significant response to this health crisis.

    Regulatory Approvals and Guidelines

    The role of regulatory approvals and clinical guidelines cannot be understated in the Global Ticagrelor Market Industry. Regulatory bodies are increasingly recognizing the efficacy of Ticagrelor, leading to expedited approvals for new indications. For instance, recent updates in clinical guidelines recommend Ticagrelor as a first-line treatment for certain patient populations. Such endorsements not only enhance the drug's credibility but also encourage healthcare providers to prescribe it more frequently. This regulatory support is expected to bolster market growth, as the industry adapts to evolving clinical practices and guidelines.

    Market Segment Insights

    Regional Insights

    Key Companies in the Ticagrelor Market market include

    Industry Developments

      • September 02, 2019, the Strs Ohio (the US), a main worldwide institutional financial backer, reported the securing of another stake in Phase Bio Pharmaceuticals Inc. (the US), a clinical-stage biopharmaceutical organization. 
      • haseBio centers around the turn of events and commercialization of novel treatments and medications, for example, an inversion specialist for the antiplatelet drug ticagrelor

    Future Outlook

    Ticagrelor Market Future Outlook

    The Global Ticagrelor Market is poised for growth at a 13.73% CAGR from 2024 to 2035, driven by increasing cardiovascular disease prevalence and advancements in drug formulations.

    New opportunities lie in:

    • Develop novel Ticagrelor combinations to enhance efficacy and reduce side effects.
    • Expand into emerging markets with tailored marketing strategies and local partnerships.
    • Invest in digital health solutions to improve patient adherence and monitoring.

    By 2035, the Ticagrelor Market is expected to achieve substantial growth, reflecting evolving healthcare needs and innovations.

    Market Segmentation

    Report Overview

    • Market Overview
    • COVID 19 Analysis
    • Market dynamics
    • Market Trends Segment Overview
    • Regional Analysis as per the Market Forecast.
    • Market Competitive Landscape
    • Developments in Market Value

    Recent Developments

    • September 02, 2019, the Strs Ohio (the US), a main worldwide institutional financial backer, reported the securing of another stake in Phase Bio Pharmaceuticals Inc. (the US), a clinical-stage biopharmaceutical organization. 
    • haseBio centers around the turn of events and commercialization of novel treatments and medications, for example, an inversion specialist for the antiplatelet drug ticagrelor

    Competitive Landscape

    • AstraZeneca, Eli Lilly
    • Ingelheim
    • Alexion
    • Roche
    • Amgen
    • Boehringer
    • Pfizer
    • Merck
    • GSK
    • Boehringer
    • Amgen

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 NA (USD Billion)
    Market Size 2024 NA (USD Billion)
    Market Size 2032 3.32 (USD Billion)
    Compound Annual Growth Rate (CAGR) 6.4 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   AstraZeneca, PLC.
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers ·  Increasing cardiovascular rate ·  Rise in the older population

    Market Highlights

    Author

    Kinjoll Dey
    Research Analyst Level I

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    At what CAGR is the ticagrelor market projected to grow in the forecast period (2023-2030)?

    Ticagrelor market projected to grow at approximately 6.4% CAGR during the assessment period (2023-2032).

    How much is the ticagrelor market worth in the future?

    The valuation of the ticagrelor market is estimated to increase to USD 3.32 Billion by the end of 2032.

    What are the major tailwinds pushing the growth of the ticagrelor market?

    Large patient pool suffering from heart problems and increasing product development, commercialization, and improving funding for R&D by the market players are major tailwinds pushing the growth of the ticagrelor market.

    Which region holds the largest share in the ticagrelor market?

    North America holds the largest share in the ticagrelor market, followed by Europe and the Asia Pacific, respectively.

    Who are the top players in the ticagrelor market?

    AstraZeneca, Eli Lilly, Boehringer, Ingelheim, Pfizer, Amgen, Merck, Roche, GSK, Boehringer, Alexion, and Amgen, are some of the top players operating in the global ticagrelor market.

    1. Report Prologue
    2. Introduction
      1. Definition 14
      2. 2.2
      3. Scope of the Study 14
      4. Research Objective 14
      5. Assumptions &
        1. Assumptions 14
        2. Limitations 14
        3. Market
      6. Limitations 14
      7. Structure 14
    3. Research Methodology
      1. Primary Research Methodology 16
      2. Secondary Research Methodology 18
      3. Market Size Estimation 19
      4. 3.4
      5. Forecast Model 19
    4. Market Dynamics
      1. Drivers 21
        1. Rising Cardiovascular
        2. Increasing Geriatric Population 22
      2. Disorders 21
      3. Restraints 22
        1. High Bleeding Complications 22
      4. Opportunities 22
        1. Exploring
      5. New Applications 22
    5. Market Factor Analysis
      1. Porter’s Five Forces
        1. Bargaining Power of Suppliers 24
        2. Bargaining Power
        3. Threat of New Entrants 25
        4. Threat of Substitutes
        5. Intensity of Rivalry 25
      2. Model 24
      3. of Buyers 25
      4. 25
      5. Value Chain Analysis 26
        1. Manufacturing 26
        2. Distribution & Sales 26
        3. Post-Sales Monitoring 26
      6. 5.2.1
      7. R&D 26
      8. Demand & Supply: Gap Analysis 27
      9. Pricing Analysis 27
      10. Investment Opportunities 27
      11. Macroeconomic
      12. Indicators 27
      13. Pipeline Analysis 28
    6. The Global Ticagrelor Market,
      1. by Dosage (Mg)
      2. Introduction 30
      3. 90 MG 31
      4. 60 MG 31
      5. 7
    7. The Ticagrelor Market, by Route of Administration
      1. Introduction 33
      2. 7.2
      3. Oral 34
      4. Nasogastric Tube 34
    8. The Ticagrelor Market, by Application
      1. Introduction 36
      2. Acute Coronary Syndrome 37
      3. Heart Surgeries
        1. Angioplasty 38
        2. Stent Placement 38
        3. Coronary Artery
      4. 37
      5. Bypass Graft 39
    9. The Ticagrelor Market, by End User
      1. Introduction
      2. 41
      3. Hospitals and Clinics 42
      4. Ambulatory Centers 42
    10. The
    11. Global Ticagrelor Market, by Region
      1. Introduction 44
      2. Americas
      3. 46
    12. The Ticagrelor Market, by Route of Administration
      1. The Ticagrelor Market,
      2. by Application
    13. The Ticagrelor Market, by End User
      1. 48
    14. North America
    15. The Ticagrelor Market, by Route of Administration
      1. The Ticagrelor Market,
      2. by Application
    16. The Ticagrelor Market, by End User
      1. The
    17. US 50
    18. Ticagrelor Market, by Route of Administration
    19. The Ticagrelor Market, by Application
    20. The Ticagrelor Market, by End User
      1. The Ticagrelor
    21. Canada 52
    22. Market, by Route of Administration
    23. The Ticagrelor Market, by Application
    24. The Ticagrelor Market, by End User
      1. The Ticagrelor
    25. South America 54
    26. Market, by Route of Administration
    27. The Ticagrelor Market, by Application
    28. The Ticagrelor Market, by End User
      1. Europe 56
      2. The Ticagrelor Market,
      3. by Route of Administration
    29. The Ticagrelor Market, by Application
      1. The Ticagrelor
    30. Market, by End User
      1. The Ticagrelor Market, by
      2. Route of Administration
    31. Western Europe 58
    32. The Ticagrelor Market, by Application
      1. The Ticagrelor
    33. Market, by End User
    34. Germany 60
    35. The Ticagrelor Market, by Route
      1. of Administration
    36. The Ticagrelor Market, by Application
      1. The Ticagrelor
    37. Market, by End User
    38. UK 62
    39. The Ticagrelor Market, by Route of
      1. Administration
    40. The Ticagrelor Market, by Application
      1. The Ticagrelor Market,
      2. by End User
    41. France 63
    42. The Ticagrelor Market, by Route of Administration
    43. The Ticagrelor Market, by Application
    44. The Ticagrelor Market, by End User
    45. Italy 65
    46. The Ticagrelor Market, by Route of Administration
      1. The
    47. Ticagrelor Market, by Application
    48. The Ticagrelor Market, by End User
      1. 10.3.1.5
      2. Spain 67
    49. The Ticagrelor Market, by Route of Administration
      1. The Ticagrelor
    50. Market, by Application
    51. The Ticagrelor Market, by End User
      1. of Western Europe 68
    52. Rest
    53. The Ticagrelor Market, by Route of Administration
      1. The
    54. Ticagrelor Market, by Application
    55. The Ticagrelor Market, by End User
      1. 10.3.2
      2. Eastern Europe 70
    56. The Ticagrelor Market, by Route of Administration
      1. The
    57. Ticagrelor Market, by Application
    58. The Ticagrelor Market, by End User
      1. 10.4
      2. Asia-Pacific 72
    59. The Ticagrelor Market, by Route of Administration
      1. The
    60. Ticagrelor Market, by Application
    61. The Ticagrelor Market, by End User
      1. 10.4.1
      2. Japan 74
    62. The Ticagrelor Market, by Route of Administration
      1. The Ticagrelor
    63. Market, by Application
    64. The Ticagrelor Market, by End User
      1. 76
    65. China
    66. The Ticagrelor Market, by Route of Administration
      1. The Ticagrelor Market,
      2. by Application
    67. The Ticagrelor Market, by End User
      1. The
    68. India 77
    69. Ticagrelor Market, by Route of Administration
    70. The Ticagrelor Market, by Application
    71. The Ticagrelor Market, by End User
      1. The Ticagrelor
    72. Australia 79
    73. Market, by Route of Administration
    74. The Ticagrelor Market, by Application
    75. The Ticagrelor Market, by End User
      1. The Ticagrelor
    76. South Korea 81
    77. Market, by Route of Administration
    78. The Ticagrelor Market, by Application
    79. The Ticagrelor Market, by End User
      1. The
    80. Rest of Asia-Pacific 82
    81. Ticagrelor Market, by Route of Administration
    82. The Ticagrelor Market, by Application
    83. The Ticagrelor Market, by End User
      1. Rest of the World 85
      2. The Ticagrelor
    84. Market, by Route of Administration
    85. The Ticagrelor Market, by Application
    86. The Ticagrelor Market, by End User
      1. The Ticagrelor
    87. Middle East 87
    88. Market, by Route of Administration
    89. The Ticagrelor Market, by Application
    90. The Ticagrelor Market, by End User
      1. The Ticagrelor Market,
      2. by Route of Administration
    91. Africa 89
    92. The Ticagrelor Market, by Application
      1. The Ticagrelor
    93. Market, by End User
      1. The Ticagrelor Market, by
      2. Route of Administration
    94. Other Countries 90
    95. The Ticagrelor Market, by Application
      1. The Ticagrelor
    96. Market, by End User
    97. Company Landscape
      1. Introduction 94
      2. 12
      3. Company Profiles
      4. AstraZeneca, PLC 96
        1. Company Overview 96
        2. Financial Overview 96
        3. Products Offering 97
        4. Key
        5. SWOT Analysis 97
        6. Key Strategy 97
      5. Developments 97
      6. 13
      7. Appendix
      8. Discussion Blue Print 99
      9. References 100
    98. List
      1. of Tables
    99. PRIMARY INTERVIEWS 17
    100. PIPELINE PRODUCTS 28
    101. GLOBAL TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 30
    102. GLOBAL TICAGRELOR MARKET FOR 90 MG, BY REGION, 2023–2030 (USD MILLION)
      1. 31
    103. GLOBAL TICAGRELOR MARKET FOR 60 MG, BY REGION, 2023–2030 (USD
      1. MILLION) 31
    104. GLOBAL TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030
      1. (USD MILLION) 33
    105. GLOBAL TICAGRELOR MARKET FOR ORAL, BY REGION, 2023–2030
      1. (USD MILLION) 34
    106. GLOBAL TICAGRELOR MARKET FOR NASOGASTRIC TUBE, BY
      1. REGION, 2023–2030 (USD MILLION) 34
    107. GLOBAL TICAGRELOR MARKET,
      1. BY APPLICATION 2023-2030 (USD MILLION) 36
    108. GLOBAL TICAGRELOR MARKET
      1. FOR ACUTE CORONARY SYNDROME, BY REGION, 2023–2030 (USD MILLION) 37
      2. TABLE
    109. GLOBAL TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION)
      1. 37
    110. GLOBAL TICAGRELOR MARKET FOR HEART SURGERIES, BY REGION 2023-2030
      1. (USD MILLION) 38
    111. GLOBAL TICAGRELOR MARKET FOR ANGIOPLASTY, BY REGION,
    112. GLOBAL TICAGRELOR MARKET FOR STENT
      1. PLACEMENT, BY REGION, 2023–2030 (USD MILLION) 38
    113. GLOBAL TICAGRELOR
    114. MARKET FOR CORONARY ARTERY BYPASS GRAFT-, BY REGION, 2023–2030 (USD MILLION)
      1. 39
    115. GLOBAL TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 41
    116. GLOBAL TICAGRELOR MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2023–2030
      1. (USD MILLION) 42
    117. GLOBAL TICAGRELOR MARKET FOR AMBULATORY CENTERS,
      1. BY REGION, 2023–2030 (USD MILLION) 42
    118. GLOBAL TICAGRELOR MARKET,
      1. BY REGION 2023-2030 (USD MILLION) 45
    119. AMERICAS TICAGRELOR MARKET, BY
      1. REGION 2023-2030 (USD MILLION) 46
    120. AMERICAS TICAGRELOR MARKET, BY DOSAGE
      1. (MG) 2023-2030 (USD MILLION) 46
    121. AMERICAS TICAGRELOR MARKET, BY ROUTE
      1. OF ADMINISTRATION 2023-2030 (USD MILLION) 47
    122. AMERICAS TICAGRELOR MARKET,
      1. BY APPLICATION 2023-2030 (USD MILLION) 47
    123. AMERICAS TICAGRELOR MARKET
      1. FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 47
    124. AMERICAS TICAGRELOR
    125. MARKET, BY END-USER 2023-2030 (USD MILLION) 48
    126. NORTH AMERICA TICAGRELOR
    127. MARKET, BY COUNTRY 2023-2030 (USD MILLION) 48
    128. NORTH AMERICA TICAGRELOR
    129. MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 49
    130. NORTH AMERICA TICAGRELOR
    131. MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 49
    132. NORTH
    133. AMERICA TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 49
      1. TABLE
    134. NORTH AMERICA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION)
      1. 49
    135. NORTH AMERICA TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION)
      1. 50
    136. US TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 50
    137. US TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION)
      1. 50
    138. US TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 51
    139. US TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION)
      1. 51
    140. US TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 51
    141. CANADA TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 52
    142. CANADA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION)
      1. 52
    143. CANADA TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION)
      1. 52
    144. CANADA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030
      1. (USD MILLION) 53
    145. CANADA TICAGRELOR MARKET, BY END-USER 2023-2030 (USD
      1. MILLION) 53
    146. SOUTH AMERICA TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030
      1. (USD MILLION) 54
    147. SOUTH AMERICA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION
    148. SOUTH AMERICA TICAGRELOR MARKET, BY APPLICATION
    149. SOUTH AMERICA TICAGRELOR MARKET FOR HEART
      1. SURGERIES, BY TYPE 2023-2030 (USD MILLION) 55
    150. SOUTH AMERICA TICAGRELOR
    151. MARKET, BY END-USER 2023-2030 (USD MILLION) 55
    152. EUROPE TICAGRELOR MARKET,
      1. BY REGION 2023-2030 (USD MILLION) 56
    153. EUROPE TICAGRELOR MARKET, BY
      1. DOSAGE (MG) 2023-2030 (USD MILLION) 56
    154. EUROPE TICAGRELOR MARKET, BY
      1. ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 57
    155. EUROPE TICAGRELOR
    156. MARKET, BY APPLICATION 2023-2030 (USD MILLION) 57
    157. EUROPE TICAGRELOR
    158. MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 57
    159. EUROPE
    160. TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 58
    161. WESTERN
    162. EUROPE TICAGRELOR MARKET, BY COUNTRY 2023-2030 (USD MILLION) 58
    163. WESTERN
    164. EUROPE TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 59
      1. TABLE 55
    165. WESTERN EUROPE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION)
      1. 59
    166. WESTERN EUROPE TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD
      1. MILLION) 59
    167. WESTERN EUROPE TICAGRELOR MARKET FOR HEART SURGERIES,
      1. BY TYPE 2023-2030 (USD MILLION) 59
    168. WESTERN EUROPE TICAGRELOR MARKET,
      1. BY END-USER 2023-2030 (USD MILLION) 60
    169. GERMANY TICAGRELOR MARKET,
      1. BY DOSAGE (MG) 2023-2030 (USD MILLION) 60
    170. GERMANY TICAGRELOR MARKET,
      1. BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 60
    171. GERMANY TICAGRELOR
    172. MARKET, BY APPLICATION 2023-2030 (USD MILLION) 61
    173. GERMANY TICAGRELOR
    174. MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 61
    175. GERMANY
    176. TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 61
    177. UK TICAGRELOR
    178. MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 62
    179. UK TICAGRELOR MARKET,
      1. BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 62
    180. UK TICAGRELOR
    181. MARKET, BY APPLICATION 2023-2030 (USD MILLION) 62
    182. UK TICAGRELOR MARKET
      1. FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 63
    183. UK TICAGRELOR
    184. MARKET, BY END-USER 2023-2030 (USD MILLION) 63
    185. FRANCE TICAGRELOR MARKET,
      1. BY DOSAGE (MG) 2023-2030 (USD MILLION) 63
    186. FRANCE TICAGRELOR MARKET,
      1. BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 64
    187. FRANCE TICAGRELOR
    188. MARKET, BY APPLICATION 2023-2030 (USD MILLION) 64
    189. FRANCE TICAGRELOR
    190. MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 64
    191. FRANCE
    192. TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 65
    193. ITALY TICAGRELOR
    194. MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 65
    195. ITALY TICAGRELOR
    196. MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 65
    197. ITALY
    198. TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 66
    199. ITALY
    200. TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 66
      1. TABLE
    201. ITALY TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 66
      1. TABLE 79
    202. SPAIN TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 67
      1. TABLE 80
    203. SPAIN TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 67
    204. SPAIN TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 67
    205. SPAIN TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION)
      1. 68
    206. SPAIN TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 68
    207. REST OF WESTERN EUROPE TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD
      1. MILLION) 68
    208. REST OF WESTERN EUROPE TICAGRELOR MARKET, BY ROUTE OF
      1. ADMINISTRATION 2023-2030 (USD MILLION) 69
    209. REST OF WESTERN EUROPE TICAGRELOR
    210. MARKET, BY APPLICATION 2023-2030 (USD MILLION) 69
    211. REST OF WESTERN
    212. EUROPE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 69
    213. REST OF WESTERN EUROPE TICAGRELOR MARKET, BY END-USER 2023-2030 (USD
      1. MILLION) 70
    214. EASTERN EUROPE TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030
      1. (USD MILLION) 70
    215. EASTERN EUROPE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION
    216. EASTERN EUROPE TICAGRELOR MARKET, BY APPLICATION
    217. EASTERN EUROPE TICAGRELOR MARKET FOR HEART
      1. SURGERIES, BY TYPE 2023-2030 (USD MILLION) 71
    218. EASTERN EUROPE TICAGRELOR
    219. MARKET, BY END-USER 2023-2030 (USD MILLION) 71
    220. ASIA-PACIFIC TICAGRELOR
    221. MARKET, BY COUNTRY 2023-2030 (USD MILLION) 72
    222. ASIA-PACIFIC TICAGRELOR
    223. MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 72
    224. ASIA-PACIFIC TICAGRELOR
    225. MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 73
    226. ASIA-PACIFIC
    227. TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 73
    228. ASIA-PACIFIC
    229. TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 73
      1. TABLE
    230. ASIA-PACIFIC TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 74
      1. TABLE
    231. JAPAN TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 74
      1. TABLE
    232. JAPAN TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION)
      1. 74
    233. JAPAN TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION)
      1. 75
    234. JAPAN TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030
      1. (USD MILLION) 75
    235. JAPAN TICAGRELOR MARKET, BY END-USER 2023-2030 (USD
      1. MILLION) 75
    236. CHINA TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD
      1. MILLION) 76
    237. CHINA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030
      1. (USD MILLION) 76
    238. CHINA TICAGRELOR MARKET, BY APPLICATION 2023-2030
      1. (USD MILLION) 76
    239. CHINA TICAGRELOR MARKET FOR HEART SURGERIES, BY
      1. TYPE 2023-2030 (USD MILLION) 77
    240. CHINA TICAGRELOR MARKET, BY END-USER
    241. INDIA TICAGRELOR MARKET, BY DOSAGE (MG)
    242. INDIA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION
    243. INDIA TICAGRELOR MARKET, BY APPLICATION
    244. INDIA TICAGRELOR MARKET FOR HEART SURGERIES,
      1. BY TYPE 2023-2030 (USD MILLION) 78
    245. INDIA TICAGRELOR MARKET, BY END-USER
    246. AUSTRALIA TICAGRELOR MARKET, BY DOSAGE
      1. (MG) 2023-2030 (USD MILLION) 79
    247. AUSTRALIA TICAGRELOR MARKET, BY ROUTE
      1. OF ADMINISTRATION 2023-2030 (USD MILLION) 79
    248. AUSTRALIA TICAGRELOR
    249. MARKET, BY APPLICATION 2023-2030 (USD MILLION) 80
    250. AUSTRALIA TICAGRELOR
    251. MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 80
    252. AUSTRALIA
    253. TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 80
    254. SOUTH KOREA
    255. TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 81
    256. SOUTH
    257. KOREA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 81
    258. SOUTH KOREA TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION)
      1. 81
    259. SOUTH KOREA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030
      1. (USD MILLION) 82
    260. SOUTH KOREA TICAGRELOR MARKET, BY END-USER 2023-2030
      1. (USD MILLION) 82
    261. REST OF ASIA-PACIFIC TICAGRELOR MARKET, BY DOSAGE
      1. (MG) 2023-2030 (USD MILLION) 82
    262. REST OF ASIA-PACIFIC TICAGRELOR MARKET,
      1. BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 83
    263. REST OF ASIA-PACIFIC
    264. TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 83
    265. REST
    266. OF ASIA-PACIFIC TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION)
      1. 83
    267. REST OF ASIA-PACIFIC TICAGRELOR MARKET, BY END-USER 2023-2030
      1. (USD MILLION) 84
    268. REST OF THE WORLDTICAGRELOR MARKET, BY REGION 2023-2030
      1. (USD MILLION) 85
    269. REST OF THE WORLDTICAGRELOR MARKET, BY DOSAGE (MG)
    270. REST OF THE WORLDTICAGRELOR MARKET, BY
      1. ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 86
    271. REST OF THE WORLDTICAGRELOR
    272. MARKET, BY APPLICATION 2023-2030 (USD MILLION) 86
    273. REST OF THE WORLDTICAGRELOR
    274. MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 86
    275. REST
    276. OF THE WORLDTICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 87
      1. TABLE
    277. MIDDLE EAST TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 87
    278. MIDDLE EAST TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030
      1. (USD MILLION) 87
    279. MIDDLE EAST TICAGRELOR MARKET, BY APPLICATION 2023-2030
      1. (USD MILLION) 88
    280. MIDDLE EAST TICAGRELOR MARKET FOR HEART SURGERIES,
      1. BY TYPE 2023-2030 (USD MILLION) 88
    281. MIDDLE EAST TICAGRELOR MARKET,
      1. BY END-USER 2023-2030 (USD MILLION) 88
    282. AFRICA TICAGRELOR MARKET,
      1. BY DOSAGE (MG) 2023-2030 (USD MILLION) 89
    283. AFRICA TICAGRELOR MARKET,
      1. BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 89
    284. AFRICA TICAGRELOR
    285. MARKET, BY APPLICATION 2023-2030 (USD MILLION) 89
    286. AFRICA TICAGRELOR
    287. MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 90
    288. AFRICA
    289. TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 90
    290. OTHER COUNTRIES
    291. TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 90
    292. OTHER
    293. COUNTRIES TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION)
      1. 91
    294. OTHER COUNTRIES TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD
      1. MILLION) 91
    295. OTHER COUNTRIES TICAGRELOR MARKET FOR HEART SURGERIES,
      1. BY TYPE 2023-2030 (USD MILLION) 91
    296. OTHER COUNTRIES TICAGRELOR MARKET,
      1. BY END-USER 2023-2030 (USD MILLION) 92
    297. List of Figures
    298. TOP-DOWN
      1. & BOTTOM-UP APPROACHES 19
    299. MARKET DYNAMICS: GLOBAL TICAGRELOR MARKET
      1. 21
    300. PORTER’S FIVE FORCES ANALYSIS: GLOBAL TICAGRELOR MARKET 24
    301. VALUE CHAIN ANALYSIS OF THE GLOBAL TICAGRELOR MARKET 26
      1. FIGURE 5
    302. GLOBAL TICAGRELOR MARKET, BY DOSAGE (MG) 2023 & 2030 (USD MILLION) 30
      1. FIGURE
    303. GLOBAL TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023 & 2030 (USD MILLION)
      1. 33
    304. GLOBAL TICAGRELOR MARKET, BY APPLICATION 2023 & 2030 (USD MILLION)
      1. 36
    305. GLOBAL TICAGRELOR MARKET, FOR HEART SURGERIES BY TYPE 2023 &
    306. GLOBAL TICAGRELOR MARKET, BY END-USER 2023 &
    307. GLOBAL TICAGRELOR MARKET, BY REGION 2023 &
    308. AMERICAS TICAGRELOR MARKET SHARE, BY REGION
    309. AMERICAS TICAGRELOR MARKET SHARE, BY COUNTRY 2023 (%)
      1. 48
    310. EUROPE TICAGRELOR MARKET, BY REGION 2023 (%) 56
      1. FIGURE 14
    311. WESTERN EUROPE TICAGRELOR MARKET, BY COUNTRY 2023 (%) 58
    312. ASIA-PACIFIC
    313. TICAGRELOR MARKET, BY COUNTRY 2023 (%) 72
    314. REST OF THE WORLDTICAGRELOR
    315. MARKET, BY REGION 2023(%) 85

    Ticagrelor Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027